Department of Neurology and Neurogeriatry, JW Klinikum Minden, Germany.
Expert Rev Neurother. 2012 Feb;12(2):169-77. doi: 10.1586/ern.11.198.
Several trials in acute stroke are underway or have been completed recently. Among the latter, ECASS 3 was a milestone regarding the extension of the rigid 3-h time window out to 4.5 h for intravenous thrombolysis with recombinant tissue plasminogen activator. Several other approaches are being tested for thrombolytic therapy, among them modern imaging-based patient selection of patients and interventional approaches. Other pharmaceutical strategies include neuroprotection, and restoration, biophysical approaches, such as near infrared laser therapy, hemodynamic augmentation, and sphenopalatine ganglion stimulation. This perspective will cover the recently completed and currently recruiting acute stroke trials with respect to their potential role in expanding the therapeutic time window for acute ischemic stroke.
几项急性中风试验正在进行或已完成。后者中，ECASS 3 是一个里程碑，它将重组组织型纤溶酶原激活剂静脉溶栓的严格 3 小时时间窗延长至 4.5 小时。其他几种溶栓治疗方法正在测试中，包括基于现代影像学的患者选择和介入方法。其他药物治疗策略包括神经保护和修复，以及生物物理方法，如近红外激光治疗、血液动力学增强和蝶腭神经节刺激。本观点将涵盖最近完成和正在招募的急性中风试验，探讨它们在扩大急性缺血性中风治疗时间窗方面的潜在作用。
